Anogen-Yes Biotech

12/18/2025

As the year comes to a close, we’d like to thank our customers, partners, and researchers around the world for your trust and collaboration throughout 2025.

We’re proud to support your work in immunology, oncology, neuroscience, and beyond, and we look forward to continuing this journey together in the year ahead.

Wishing you a joyful holiday season and a successful, inspiring New Year!

🎄❄️✨

12/03/2025

Latest data from the 2025 CTAD conference shows that Eisai’s anti-tau antibody Etalanetug (E2814) dramatically reduces eMTBR-tau243 levels — a blood and CSF biomarker tightly linked to tau tangles — in patients with inherited Alzheimer’s disease. Results suggest tau spreading was inhibited, hinting at real disease-modifying potential for tauopathies.

📉 CSF tau-tangle biomarker down ~62 % at 3 months
📉 Plasma biomarker down ~78 % at 3 months, improving over time

This could pave the way for blood-based monitoring of tau pathology and new therapeutic strategies for Alzheimer’s and related tau disorders.

Read the full article here: https://media-us.eisai.com/2025-12-01-Eisai-Presents-New-Data-on-Anti-Tau-Antibody-Etalanetug-E2814-at-CTAD-2025

Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase Ib/II study TOKYO, Dec. 1, 2025 /PRNewswire/ -- Eisai...

11/26/2025

New insights in immune-modulation! A recent Journal of Leukocyte Biology review highlights how anti-TNF therapy doesn’t just neutralize TNF-α — it also reprograms innate immune cells, offering hope for treating systemic autoinflammatory diseases. 🔄 By targeting the root of inflammation, this approach could reshape standards for immune-disease treatment.

Read the full article here: https://academic.oup.com/jleukbio/article-abstract/117/5/qiaf026/8078379

This review explores the clinical relevance of anti-tumor necrosis factor therapy in systemic autoinflammatory diseases, focusing on its impact on innate i

11/19/2025

🔬 New must-read for Alzheimer’s researchers! A fresh review in Alzheimer’s Disease: Clinical Trials to Watch spotlights next-gen therapies tackling tau, amyloid-β, and neuro-inflammation. Better trial design + smarter biomarkers = real hope for AD.
🔗 https://www.sciencedirect.com/science/article/abs/pii/S2666634025001989

11/12/2025

Tsutomu Takeuchi’s article highlights next-gen anti-TNF agents, including nanobody therapeutics like Ozoralizumab, and what’s “new vs old” in RA treatment. Dive into the evolving pipeline and future of TNF-targeted therapy.

Read the full article: https://pubmed.ncbi.nlm.nih.gov/40180877/

This review summarizes the recent advancement of fragmented immunoglobulin molecules targeting on Tumot Necrosis Factor (TNF) alpha and highlighted the nanobody, which is the first approved product for the patients with rheumatoid arthritis (RA), ozoralizumab (OZR). Background for the clinical devel...

11/05/2025

The FDA now allows patients with multiple sclerosis to self-administer the intranasal antibody Foralumab at home — a first of its kind in anti-CD3 therapy.

This breakthrough drug modulates T-cell activity via nasal delivery, offering a more convenient alternative to clinic-based infusions and potentially boosting patient adherence and outcomes.

With strong safety signals and promising early efficacy in na-SPMS patients, this shift into home dosing could transform how MS is managed.

🔗 Read more: https://www.globenewswire.com/news-release/2023/10/18/2762186/0/en/Tiziana-Life-Sciences-Announces-Allowance-By-FDA-For-At-Home-Dosing-Of-Intranasal-Foralumab-For-Multiple-Sclerosis-Treatment.html?utm_source=chatgpt.com

10/29/2025

A recent Nature Communications (IF 15.4) study by Bao et al., Shanghai Jiao Tong University introduces a groundbreaking neuromorphic electro-stimulation (ES) approach based on atomically thin semiconductors.
This innovation successfully suppresses inflammation without tissue damage, offering a new paradigm for bioelectronic medicine.

📊 Using Anogen’s Mouse ELISA Kits —
• TNF-α (MEC1003)
• IL-6 (MEC1008)
• IL-1β (MEC1010)
the researchers quantitatively confirmed dramatic reductions in pro-inflammatory cytokines:
IL-6 decreased by up to 73.5% after neuromorphic stimulation compared with non-stimulated controls.

🧩 The ELISA data provided by Anogen kits were critical in:

Revealing the Adrb2-dependent signaling mechanism underlying inflammation modulation (Fig. 1e–g)

These results underscore how Anogen’s high-sensitivity cytokine ELISA kits empower researchers to quantify subtle immune responses with precision — supporting world-class innovations in immunology, neuroscience, and bioelectronics.

📖 Bao R., Wang S., et al. (2024). “Neuromorphic electro-stimulation based on atomically thin semiconductor for damage-free inflammation inhibition.” Nature Communications 15, 1327.

🔗 Read on PubMed： https://www.nature.com/articles/s41467-024-45590-8

🔗 Explore Anogen ELISA Kits：https://www.anogen.ca

10/22/2025

A recent study takes a deep look at the evolving therapeutic landscape of tauopathies, a group of neurodegenerative diseases driven by abnormal tau protein aggregation.

📊 Researchers identified around 170 drug candidates currently in development — including 5 in Phase III, 15 in Phase II, and 12 in Phase I clinical trials. While no disease-modifying treatments have been approved yet, the field remains highly active.

🔍 The paper also highlights progress in tau PET imaging biomarkers, with one FDA-approved tracer (Tauvid™) and several others advancing through development — a key step toward better diagnosis and trial monitoring.

Although challenges remain, these findings underscore steady momentum and growing optimism in the fight against tau-related neurodegenerative disorders.

Read the full article: https://pubmed.ncbi.nlm.nih.gov/40462159/

Microtubule associated protein tau (MAPT) is a naturally occurring protein that plays a significant role in stabilizing microtubules, which are essential for the transport of nutrients and other materials within neurons. In tauopathies, tau protein assembles into mis-folded multimers ranging from so...

10/15/2025

🧠 A recent Nature Reviews Drug Discovery article outlines a bold vision for the future of AD therapies — expanding beyond amyloid-β to target Tau, ApoE, and α-synuclein, and harnessing next-gen tools like protein degraders, RNA drugs, and brain-penetrant antibodies.

Collaboration and innovation will drive the next wave of breakthroughs.

🔗 Read more: https://pubmed.ncbi.nlm.nih.gov/40770764/

After decades of disappointment, three disease-modifying therapies for Alzheimer's disease (AD) have been approved since 2021. Burgeoning clinical data on these amyloid β-protein (Aβ) targeting drugs validate the amyloid cascade hypothesis as a molecular roadmap for the development of yet more eff...

10/08/2025

A review in Neural Regeneration Research highlights how targeting tau protein—a key driver of neurodegeneration—may unlock new, earlier, and safer treatment strategies for Alzheimer’s disease.

Read the full article here: https://pubmed.ncbi.nlm.nih.gov/38051891/

Alzheimer's disease is the most prevalent neurodegenerative disease affecting older adults. Primary features of Alzheimer's disease include extracellular aggregation of amyloid-β plaques and the accumulation of neurofibrillary tangles, formed by tau protein, in the cells. While there are amyloid-β...

10/01/2025

🎉 Anogen W.X. LifeAntibody Solution Ltd. is honored to be an official sponsor of the 5th CBA Canada Annual Conference!

On September 27, 2025, we proudly joined this successful event in Toronto. By supporting this conference, we aim to collaborate with global experts, scholars, and industry partners to explore the limitless possibilities of biotechnology.

As a company dedicated to biotech innovation, Anogen is committed to advancing life sciences through cutting-edge research and solutions. We firmly believe that collaboration and knowledge exchange are key drivers of progress in our industry.

🌐 Learn more: www.anogen.ca

09/22/2025

A Frontiers in Pharmacology analysis of FAERS data (2004–2024) highlights potential thrombotic risks linked to TNF-α blockers. The research found safety signals across patient groups, stressing the need for careful monitoring of clotting events in real-world use.

🔗 Read on PubMed: https://pubmed.ncbi.nlm.nih.gov/40351429/

This study suggests that TNF - α blockers are associated with various adverse events of thrombosis, with different risks in different patient groups and treatment stages. Clinical doctors should assess individual thrombosis risk and closely monitor coagulation related indicators when using TNF - α...